NEW YORK (GenomeWeb News) – MolecularMD has submitted a Premarket Approval application with the US Food and Drug Administration for a companion diagnostic test to leukemia drug ponatinib.

The Portland, Ore.-based firm said after the close of the market Monday that it had filed for clearance of its BCR-ABL T315I Mutation Test, which detects the T315I mutation in BCR-ABL RNA transcripts in blood using Sanger sequencing technology. It said the test can identify patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia who have the mutation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.